← Leaderboards
Patrick Paddison
Fred Hutchinson Cancer Center
$7,763,415
Attributed
$8,298,997
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,298,997 · 7
By mechanism
R01$7,198,328 · 4
P30$682,304 · 2
R21$418,365 · 1
Top collaborators
- Jun Zhu2 shared
- Jennifer G Deluca1 shared
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesCellsMolecularGrantSamplingComplexResourcesReporterPublic HealthExperimental StudyGlioblastomaBrain NeoplasmsMalignant NeoplasmsTumorPhenotypeRegulationStandard Of CareGene ExpressionTherapeutic TargetIn VivoNeoplastic CellGliomaResistanceChromatin
Grant awards (23)
MAPK-driven kinetochore stress in cancer$652,799
R01 · FY2025 · CA · contact PI
Defining cellular states of quiescence in human brain tumors$515,443
R01 · FY2025 · NS · contact PI
Defining cellular states of quiescence in human brain tumors$499,981
R01 · FY2024 · NS · contact PI
Defining cellular states of quiescence in human brain tumors$515,443
R01 · FY2023 · NS · contact PI
Epitranscriptomic control of erythropoiesis$440,000
R01 · FY2022 · DK · contact PI
Defining cellular states of quiescence in human brain tumors$334,304
R01 · FY2022 · NS · contact PI
Defining cellular states of quiescence in human brain tumors$183,754
R01 · FY2022 · NS · contact PI
Defining cellular states of quiescence in human brain tumors$553,130
R01 · FY2021 · NS · contact PI
Epitranscriptomic control of erythropoiesis$377,360
R01 · FY2021 · DK · contact PI
Epitranscriptomic control of erythropoiesis$62,640
R01 · FY2021 · DK · contact PI
Epitranscriptomic control of erythropoiesis$440,000
R01 · FY2020 · DK · contact PI
Epitranscriptomic control of erythropoiesis$440,000
R01 · FY2019 · DK · contact PI
MYC-dependent loss of splicing fidelity in Glioblastoma multiforme$394,201
R01 · FY2019 · CA · contact PI
MYC-dependent loss of splicing fidelity in Glioblastoma multiforme$413,098
R01 · FY2018 · CA · contact PI
MYC-dependent loss of splicing fidelity in Glioblastoma multiforme$439,976
R01 · FY2017 · CA · contact PI
MYC-dependent loss of splicing fidelity in Glioblastoma multiforme$471,895
R01 · FY2016 · CA · contact PI
MYC-dependent loss of splicing fidelity in Glioblastoma multiforme$464,304
R01 · FY2015 · CA · contact PI
Core F: Canine Cell & Molecular Resources$169,254
P30 · FY2014 · DK · contact PI
Evolution of cancer-specific molecular requirements for glioblastoma multiforme ($176,645
R21 · FY2013 · CA · contact PI
Core F: Canine Cell & Molecular Resources$165,456
P30 · FY2013 · DK · contact PI
Evolution of cancer-specific molecular requirements for glioblastoma multiforme ($241,720
R21 · FY2012 · CA · contact PI
Core F: Canine Cell & Molecular Resources$174,813
P30 · FY2012 · DK · contact PI
Core F: Canine Cell & Molecular Resources$172,781
P30 · FY2010 · DK · contact PI